Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma



Status:Active, not recruiting
Conditions:Cancer, Cancer, Cancer, Kidney Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 100
Updated:4/6/2019
Start Date:October 2015
End Date:June 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
In this study the investigators aim to evaluate diagnostic utility of PSMA-targeted
18F-DCFPyL PET/CT in patients with renal cell carcinoma.


Inclusion Criteria:

- Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma

- Completed staging evaluation with computed tomography (CT) or magnetic resonance
imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment

Exclusion Criteria:

- History of other malignancy diagnosed within the last 3 years (with the exception of
low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell
carcinoma or basal cell carcinoma of the skin)

- Administered a radioisotope within 5 physical half-lives prior to study enrollment

- Pregnancy ((as determined in accordance with the policies of the positron emission
tomography (PET) center))

- Intention to enroll in a blinded therapeutic clinical trial following Positron
emission tomography-computed tomography (PET/CT)
We found this trial at
1
site
Johns Hopkins Hospital
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Mohamad E. Allaf, M.D.
Phone: 410-614-8151
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials